Markets

Sanofi's (SNY) Cerdelga FDA Approved for Gaucher Disease - Analyst Blog

Sanofi ( SNY ) announced that the FDA has approved Cerdelga for the treatment of Gaucher disease type 1. However, the drug is not indicated for adults suffering from Gaucher disease type 1 who metabolize Cerdelga very quickly or at an undetermined rate, as detected by an FDA approved test. The company is planning to launch Cerdelga in a month.

Approval of Cerdelga marks the approval of the only first-line oral therapy for adult Gaucher disease type 1 patients. Currently, intravenous enzyme replacement therapies are the standard of care for Gaucher disease. Currently approved drugs for the treatment of Gaucher disease include Sanofi's Cerezyme and Shire's ( SHPG ) Vpriv among others.

Thus, Cerdelga will provide Gaucher disease patients with an alternative and more convenient treatment option. As per the company press release, globally Gaucher disease affects fewer than 10,000 people with type 1 being the most common form of the disease.

The FDA approved Cerdelga on the basis of efficacy data from two positive phase III studies.

Our Take

We are pleased with the approval of Cerdelga. We believe that the drug will complement Sanofi's portfolio which includes Gaucher disease product Cerezyme. Cerezyme generated revenues of €343 million in the first half of 2014, up 7.9% from the year-ago period.

Sanofi presently carries a Zacks Rank #3 (Hold). Some better-ranked stocks in the health care sector include Allergan ( AGN ) and AstraZeneca ( AZN ). While Allergan carries a Zacks Rank #1 (Strong Buy), AstraZeneca is a Zacks Rank #2 (Buy) stock.

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

SANOFI-AVENTIS (SNY): Free Stock Analysis Report

SHIRE PLC-ADR (SHPG): Free Stock Analysis Report

ASTRAZENECA PLC (AZN): Free Stock Analysis Report

ALLERGAN INC (AGN): Free Stock Analysis Report

To read this article on Zacks.com click here.

Zacks Investment Research

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.


The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

In This Story

AZN SNY

Other Topics

Stocks

Latest Markets Videos

    Zacks

    Zacks is the leading investment research firm focusing on stock research, analysis and recommendations. In 1978, our founder discovered the power of earnings estimate revisions to enable profitable investment decisions. Today, that discovery is still the heart of the Zacks Rank. A wealth of resources for individual investors is available at www.zacks.com.

    Learn More